Ponad 7000 publikacji medycznych!
Statystyki za 2021 rok:
odsłony: 8 805 378
Artykuły w Czytelni Medycznej o SARS-CoV-2/Covid-19

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu tutaj
© Borgis - Medycyna Rodzinna 1/2004, s. 7-12
Zygmunt Chodorowski
Nadciśnienie tętnicze u osób w wieku podeszłym
Arteliar hypertension in the elderly
z I Katedry i Kliniki Chorób Wewnętrznych Akademii Medycznej w Gdańsku
Kierownik Katedry: prof. hab. n. med. Zygmunt Chodorowski
Summary
Arterial hypertension, and particularly its isolated systolic type, is a common disease in the the elderly and accounts for 60-70% of the old age population. The present paper includes the latest recommedations of the 7th report of the JNC, the European Society of Hypertension, and the European Society of Cardiology, which highlight the need for combination therapy with two or more antihypertensive drugs.
The choice of single-drug or combination therapy should be individually adjusted and should consider risk factors of atherosclerosis, concomitant diseases, response to treatment and the quality of life.
The most effective treatment of elderly hypertensive patients appears to be the therapy with thiazide diuretics, although any pharmaceutical agents of four main antihypertensive drug groups used in many studies have shown equal benefits. At present, only alpha-adrenolytics seem to have lost their popularity, and are not recommended in single-drug but only in combination therapy.
Angiotensin converting enzyme inhibitors are particularly indicated in left ventricular systolic dysfunction, previous myocardial infarction, diabetic nephropathy, and glomerular nephropathies.
To ensure prevention and nephroprotection in patients with type 2 diabetes and arterial hypertension, angiotensin receptor antagonists are mainly recommended.

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.
Mam kod dostępu
  • Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu albo wszystkich artykułów (w zależności od wybranej opcji), należy wprowadzić kod.
  • Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.
  • Aby kupić kod proszę skorzystać z jednej z poniższych opcji.

Opcja #1

19

Wybieram
  • dostęp do tego artykułu
  • dostęp na 7 dni

uzyskany kod musi być wprowadzony na stronie artykułu, do którego został wykupiony

Opcja #2

49

Wybieram
  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 30 dni
  • najpopularniejsza opcja

Opcja #3

119

Wybieram
  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 90 dni
  • oszczędzasz 28 zł
Piśmiennictwo
1. Wolz M. et al.: Statement from the National High Blood Pressure Education Program: prevalence of hypertension. Am. J. Hypertens. 2000; 13:103-4. 2. Izzo J.L. Jr et al.: Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension 2000; 35:1021-4. 3. Pickering T.G. et al.: Blood Pressure Monitoring. Task force V: White-coat hypertension. Blood Press Monit. 1999; 4:333-41. 4. Carretero O.A., Oparil S.: Essential hypertension: part II: treatment. Circulation 2000; 101:446-53. 5. Verdecchia P.: Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension 2000; 35:844-51. 6. Frohlich E.D.: Recognition of systolic hypertension for hypertension. Hypertension 2000; 35:1019-20. 7. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 2003; 21:1011-53. 8. Chobanian A.V. et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-72. 9. Lewington S. et al.: Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-13. 10. Wang J.G. et al.: Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch. Intern. Med. 2000; 160:211-20. 11. Hansson L. et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-6. 12. Staessen J.A. et al.: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355:865-72. 13. Mancia G., Grassi G.: Systolic and diastolic blood pressure control in antihypertensive drug trials. J. Hypertens. 2002; 20:1461-4. 14. Fagard R.H. et al.: Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J. Hypertens. 2002; 20:1297-302. 15. Ben-Dov I. et al.: Marked weight reduction lowers resting and exercise blood pressure in morbidly obese subjects. Am. J. Hypertens. 2000; 13:251-5. 16. He J. et al.: Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000; 35:544-9. 17. Kelley G.A., Kelley K.S.: Progressive resistance exercise and resting blood pressure: A meta-analysis of randomized controlled trials. Hypertension 2000; 35:838-43. 18. Taylor-Tolbert N.S. et al.: Ambulatory blood pressure after acute extercise in older men with essential hypertension. Am. J. Hypertens. 2000; 13:44-51. 19. Sacks F.M. et al.: DASH-Sodium Collaborative Research Group: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N. Engl. J. Med. 2001; 344:3-10. 20. Fagard R.H.: Exercise characteristics and the blood pressure response to dynamic physical training. Med. Sci. Sports Exerc. 2001; 33, suppl. 6:S484-92. 21. Ridker P.M.: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363-9. 22. American Diabetes Association: Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26, suppl.: 1:S80-82. 23. National Kidney Foundation Guideline. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am. J. Kidney Dis. 2002; 39, suppl. 2:S1-246. 24. Cushman W.C. et al.: ALLHAT Collaborative Research Group: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J. Clin. Hypertens. 2002; 4:393-404. 25. Black H.R. et al.: Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial. Hypertension 2001; 37:12-18. 26. Hyman D.J., Pavik V.N.: Characteristics of patients with uncontrolled hypertension in the United States. N. Engl. J. Med. 2001; 345:479-86. 27. Somes G.W. et al.: The role of diastolic blood pressure when treating idolated systolic hypertension. Arch. Intern. Med. 1999; 159:2004-9. 28. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-41. 29. Yusuf S. et al.: Effects of an angiotension-converting-enzyme inhibitor, rahibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000; 342:145-53. 30. Schrier R.W. et al.: Effects of aggressive blood pressure control in normotensive type 2 diabetic ppatients on albuminuria, retinopathy and strokes. Kidney Int. 2002; 61:1086-97. 31. Weir M.R., Moser M.: Diuretics and beta-blockers: is there a risk for dyslipidemia? Am. Heart J. 2000; 139:174-83. 32. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-97. 33. Psaty B.M. et al.: Cardiovascular Health Study. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. Arch. Intern. Med. 2002; 162:2325-32. 34. White W.B.: Benefits of antihypertensive therapy in older patients with hypertension. Arch. Intern. Med. 2000; 160:149-50. 35. MacMahon S.: Blood pressure and the risk of cardiovascular disease. N. Engl. J. Med. 2000; 342:50-2. 36. Staessen J.A. et al.: Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J. Hypertens. 2003; 21:1055-76. 37. Tuomilehto J. et al.: Effect of calcium-channel blockade in older patients with diabetes abd systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N. Engl. J. Med. 1999; 340:677-84. 38. Dahlof B. et al.: LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:995-1003. 39. Kjeldsen S.E. et al.: LIFE (Losartan Intervention for Endpoint reduction) Study Group. Effects of losartan on cardiovascular and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288:1491-8. 40. Ghiadoni L. et al.: Effects of the angiotensin II type 1 receptor blocked candesartan on endothelial function in patients with essential hypertension. Hypertension 2000; 35:501-6. 41. Kawano Y. et al.: Interaction of alcohol and an alpha1-blocker on ambulatory blood pressure in patients with essential hypertension. Am. J. Hypertens. 2000; 13:307-12. 42. Dargie H.J.: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357:1385-90. 43. Pitt B. et al.: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348:1309-21. 44. Andrejak M. et al.: Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen. Am. J. Hypertens. 2000; 13:184-90. 45. Barrier P.A. et al.: Two words to improve physician-patient communication: what else? Mayo Clin. Proc. 2003; 78:211-4.
Medycyna Rodzinna 1/2004
Strona internetowa czasopisma Medycyna Rodzinna